Sickle Cell Disease
L-Glutamine oral treatment with or without hydroxyurea reduces pain crises better than placebo in individuals with sickle cell disease.
In adults with sickle cell disease, higher daily opioid use may be associated with poorer health-related quality of life.
Olinciguat is a soluble guanylate cyclase stimulator currently in Phase 2 development.
In patients with sickle cell disease, review of intermittent pain diaries using a single random day per week or a single week per month was shown to be comparable to review of 5 months' worth of pain diaries.
The FDA has approved Endari to reduce acute complications of sickle cell disease in patients aged ≥5 years.
A new evidence-based classification system for chronic sickle cell disease pain was recently published.
Crizanlizumab therapy resulted in a significantly lower rate of sickle cell-related pain crises.
Clinical Pain Advisor Articles
- Abuse-Deterrent Opioid Formulations: Barriers to Broader Use
- Women Frequently Prescribed High Doses of Opioids After Vaginal Delivery
- Notifications by PDMPs May Not Effectively Reduce Opioid Misuse
- Virtual Reality May Effectively Reduce Sensory, Affective, and Cognitive Pain During Labor
- Electroacupuncture May Help Reduce Opioid Use in Chronic Musculoskeletal Pain
- Neuropathic Pain Medications
- Higher Buprenorphine Dose May Not Increase Severity of Neonatal Abstinence Syndrome
- Terms Used for Addiction May Be Associated With Explicit, Implicit Bias
- Ketamine Infusions May Be Effective for Refractory Headache
- Physical, Psychosocial Activity May Be Protective Against Development of Chronic Pain in Older Adults
- Opioid Use Disorder Prevalence at Delivery on the Rise in the US, According to CDC
- Suprazygomatic Sphenopalatine Ganglion Block May Quickly Relieve Status Migrainosus Pain
- Pharmacologically Induced Headache Accompanied by Dilated Cephalic Vessels
- IV Lidocaine May Be Safe, Efficacious for Pediatric Status Migraine
- Gray Matter Changes in Migraine Associated With Clinical Characteristics